Blog

  • Guide to ‘Waiting for Godot’ on Broadway starring Keanu Reeves and Alex Winter

    Guide to ‘Waiting for Godot’ on Broadway starring Keanu Reeves and Alex Winter

    Cue up another excellent adventure. Keanu Reeves and Alex Winter, two individually renowned screen actors jointly famous for their Bill & Ted films, are now taking the stage in a new production of Waiting for Godot on Broadway, one that marks Reeves’s Broadway debut and Winter’s return after 40-plus years.

    The longtime real-life pals lead Samuel Beckett’s absurdist classic about two hapless vagabonds endlessly anticipating a no-show’s arrival. Tony Award nominee Jamie Lloyd (Sunset Boulevard), a director who makes the most of minimalist stagings, steers the starry revival at the Hudson Theatre.

    Learn more about the play and its storied history with the FAQs below, and don’t wait to secure your seats on New York Theatre Guide.

    Get Waiting for Godot tickets now.

    Continue Reading

  • Targeting MHC-E as a new strategy for vaccines and immunotherapeutics

    Targeting MHC-E as a new strategy for vaccines and immunotherapeutics

  • Trowsdale, J. & Knight, J. C. Major histocompatibility complex genomics and human disease. Annu. Rev. Genom. Hum. Genet. 14, 301–323 (2013).

    Article 
    CAS 

    Google Scholar 

  • D’Souza, M. P. et al. Casting a wider net: immunosurveillance by nonclassical MHC molecules. PLoS Pathog. 15, e1007567 (2019).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Braud, V. M. et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 391, 795–799 (1998).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Borrego, F., Ulbrecht, M., Weiss, E. H., Coligan, J. E. & Brooks, A. G. Recognition of human histocompatibility leukocyte antigen (HLA)-E complexed with HLA class I signal sequence-derived peptides by CD94/NKG2 confers protection from natural killer cell-mediated lysis. J. Exp. Med. 187, 813–818 (1998).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Lee, N. et al. HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A. Proc. Natl Acad. Sci. USA 95, 5199–5204 (1998). This seminal study, together with Braud et al. (1998) and Borrego et al. (1998), identifies the role of HLA-E binding to CD94–NKG2A and CD94–NKG2C in modulating NK cell activation according to levels of HLA-Ia signal sequence presentation on the target cell.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Aldrich, C. J. et al. Identification of a Tap-dependent leader peptide recognized by alloreactive T cells specific for a class Ib antigen. Cell 79, 649–658 (1994).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Lee, N., Goodlett, D. R., Ishitani, A., Marquardt, H. & Geraghty, D. E. HLA-E surface expression depends on binding of TAP-dependent peptides derived from certain HLA class I signal sequences. J. Immunol. 160, 4951–4960 (1998).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Braud, V., Jones, E. Y. & McMichael, A. The human major histocompatibility complex class Ib molecule HLA-E binds signal sequence-derived peptides with primary anchor residues at positions 2 and 9. Eur. J. Immunol. 27, 1164–1169 (1997).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Knapp, L. A., Cadavid, L. F. & Watkins, D. I. The MHC-E locus is the most well conserved of all known primate class I histocompatibility genes. J. Immunol. 160, 189–196 (1998).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Geraghty, D. E., Stockschleader, M., Ishitani, A. & Hansen, J. A. Polymorphism at the HLA-E locus predates most HLA-A and -B polymorphism. Hum. Immunol. 33, 174–184 (1992).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Strong, R. K. et al. HLA-E allelic variants. Correlating differential expression, peptide affinities, crystal structures, and thermal stabilities. J. Biol. Chem. 278, 5082–5090 (2003).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Gillespie, G. M., Quastel, M. N. & McMichael, A. J. HLA-E: immune receptor functional mechanisms revealed by structural studies. Immunol. Rev. 329, e13434 (2025). This work provides a comprehensive review of structural and biochemical studies of HLA-E.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • van Hall, T., Oliveira, C. C., Joosten, S. A. & Ottenhoff, T. H. The other Janus face of Qa-1 and HLA-E: diverse peptide repertoires in times of stress. Microbes Infect. 12, 910–918 (2010).

    Article 
    PubMed 

    Google Scholar 

  • Wei, X. H. & Orr, H. T. Differential expression of HLA-E, HLA-F, and HLA-G transcripts in human tissue. Hum. Immunol. 29, 131–142 (1990).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Middelburg, J. et al. The MHC-E peptide ligands for checkpoint CD94/NKG2A are governed by inflammatory signals, whereas LILRB1/2 receptors are peptide indifferent. Cell Rep. 42, 113516 (2023). This paper shows that MHC-E is a ligand for inhibitory receptors LIR1 and LIR2 irrespective of peptide ligand. Using CRISPR screening, the authors also identify gene products involved in processing of VL9 peptides.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Braud, V. M., Allan, D. S., Wilson, D. & McMichael, A. J. TAP- and tapasin-dependent HLA-E surface expression correlates with the binding of an MHC class I leader peptide. Curr. Biol. 8, 1–10 (1998).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • He, W. et al. Intracellular trafficking of HLA-E and its regulation. J. Exp. Med. 220, e20221941 (2023). This study shows that the cytoplasmic tail of HLA-E contains internalization signals, which explains the short half-life of HLA-E on the cell surface.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Phillips, J. H. et al. CD94 and a novel associated protein (94AP) form a NK cell receptor involved in the recognition of HLA-A, HLA-B, and HLA-C allotypes. Immunity 5, 163–172 (1996).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Le Drean, E. et al. Inhibition of antigen-induced T cell response and antibody-induced NK cell cytotoxicity by NKG2A: association of NKG2A with SHP-1 and SHP-2 protein-tyrosine phosphatases. Eur. J. Immunol. 28, 264–276 (1998).

    Article 
    PubMed 

    Google Scholar 

  • Carretero, M. et al. Specific engagement of the CD94/NKG2-A killer inhibitory receptor by the HLA-E class Ib molecule induces SHP-1 phosphatase recruitment to tyrosine-phosphorylated NKG2-A: evidence for receptor function in heterologous transfectants. Eur. J. Immunol. 28, 1280–1291 (1998).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Lanier, L. L., Corliss, B., Wu, J. & Phillips, J. H. Association of DAP12 with activating CD94/NKG2C NK cell receptors. Immunity 8, 693–701 (1998).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Horowitz, A. et al. Genetic and environmental determinants of human NK cell diversity revealed by mass cytometry. Sci. Transl. Med. 5, 208ra145 (2013).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Mingari, M. C. et al. HLA class I-specific inhibitory receptors in human T lymphocytes: interleukin 15-induced expression of CD94/NKG2A in superantigen- or alloantigen-activated CD8+ T cells. Proc. Natl Acad. Sci. USA 95, 1172–1177 (1998).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Andre, P. et al. Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells. Cell 175, 1731–1743.e13 (2018). This study shows that HLA-E–NKG2A is a new immune checkpoint for cancer therapy because blocking NKG2A increases the anti-tumour activity of NK cells and of tumour-specific T cells, including those induced by cancer vaccines.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Kaiser, B. K., Pizarro, J. C., Kerns, J. & Strong, R. K. Structural basis for NKG2A/CD94 recognition of HLA-E. Proc. Natl Acad. Sci. USA 105, 6696–6701 (2008).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Kaiser, B. K. et al. Interactions between NKG2x immunoreceptors and HLA-E ligands display overlapping affinities and thermodynamics. J. Immunol. 174, 2878–2884 (2005).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • MacLachlan, B. J., Sullivan, L. C., Brooks, A. G., Rossjohn, J. & Vivian, J. P. Structure of the murine CD94-NKG2A receptor in complex with Qa-1b presenting an MHC-I leader peptide. FEBS J. 291, 1530–1544 (2024). This paper shows that the high-resolution structure of CD94–NKG2A with the murine MHC-E homologue Qa-1b shows similarities and differences compared with their human counterparts, thus paving the way for a humanized mouse.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Michaëlsson, J. et al. A signal peptide derived from hsp60 binds HLA-E and interferes with CD94/NKG2A recognition. J. Exp. Med. 196, 1403–1414 (2002).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Huisman, B. D. et al. High-throughput characterization of HLA-E-presented CD94/NKG2x ligands reveals peptides which modulate NK cell activation. Nat. Commun. 14, 4809 (2023). This work has developed a systematic screen of peptides binding to HLA-E and their effect on receptor binding that reveals differential peptide specificities of CD94–NKG2A and CD94–NKG2C.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Willcox, B. E., Thomas, L. M. & Bjorkman, P. J. Crystal structure of HLA-A2 bound to LIR-1, a host and viral major histocompatibility complex receptor. Nat. Immunol. 4, 913–919 (2003).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Shiroishi, M. et al. Human inhibitory receptors Ig-like transcript 2 (ILT2) and ILT4 compete with CD8 for MHC class I binding and bind preferentially to HLA-G. Proc. Natl Acad. Sci. USA 100, 8856–8861 (2003).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Horowitz, A. et al. Class I HLA haplotypes form two schools that educate NK cells in different ways. Sci. Immunol. 1, eaag1672 (2016).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Lin, Z. et al. HLA class I signal peptide polymorphism determines the level of CD94/NKG2-HLA-E-mediated regulation of effector cell responses. Nat. Immunol. 24, 1087–1097 (2023). This work shows that VL9 sequence polymorphism in HLA alleles is reflected in HCMV UL40 VL9 and impacts NK cell responses.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Cazzetta, V., Depierreux, D., Colucci, F., Mikulak, J. & Mavilio, D. NKG2A immune checkpoint in Vδ2 T cells: emerging application in cancer immunotherapy. Cancers 15, 1264 (2023).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Rapaport, A. S. et al. The inhibitory receptor NKG2A sustains virus-specific CD8+ T cells in response to a lethal poxvirus infection. Immunity 43, 1112–1124 (2015).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Zhang, X., Feng, J., Chen, S., Yang, H. & Dong, Z. Synergized regulation of NK cell education by NKG2A and specific Ly49 family members. Nat. Commun. 10, 5010 (2019).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Kaulfuss, M. et al. The NK cell checkpoint NKG2A maintains expansion capacity of human NK cells. Sci. Rep. 13, 10555 (2023).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Siemaszko, J., Marzec-Przyszlak, A. & Bogunia-Kubik, K. Activating NKG2C receptor: functional characteristics and current strategies in clinical applications. Arch. Immunol. Ther. Exp. 71, 9 (2023).

    Article 
    CAS 

    Google Scholar 

  • Lauterbach, N., Wieten, L., Popeijus, H. E., Voorter, C. E. & Tilanus, M. G. HLA-E regulates NKG2C+ natural killer cell function through presentation of a restricted peptide repertoire. Hum. Immunol. 76, 578–586 (2015).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Rolle, A., Meyer, M., Calderazzo, S., Jager, D. & Momburg, F. Distinct HLA-E peptide complexes modify antibody-driven effector functions of adaptive NK cells. Cell Rep. 24, 1967–1976.e4 (2018). This study shows that the HLA-E ligandome affects the activity and proliferation of NKG2C+ NK cells.

    Article 
    PubMed 

    Google Scholar 

  • Lopez-Verges, S. et al. Expansion of a unique CD57+NKG2Chi natural killer cell subset during acute human cytomegalovirus infection. Proc. Natl Acad. Sci. USA 108, 14725–14732 (2011).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Foley, B. et al. Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function. Blood 119, 2665–2674 (2012).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Lopez-Botet, M., De Maria, A., Muntasell, A., Della Chiesa, M. & Vilches, C. Adaptive NK cell response to human cytomegalovirus: facts and open issues. Semin. Immunol. 65, 101706 (2023). This paper provides a comprehensive review of HCMV-induced adaptive NK cells.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Della Chiesa, M. et al. Human cytomegalovirus infection promotes rapid maturation of NK cells expressing activating killer Ig-like receptor in patients transplanted with NKG2C−/− umbilical cord blood. J. Immunol. 192, 1471–1479 (2014).

    Article 
    PubMed 

    Google Scholar 

  • Luetke-Eversloh, M. et al. Human cytomegalovirus drives epigenetic imprinting of the IFNG locus in NKG2Chi natural killer cells. PLoS Pathog. 10, e1004441 (2014).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Lee, J. et al. Epigenetic modification and antibody-dependent expansion of memory-like NK cells in human cytomegalovirus-infected individuals. Immunity 42, 431–442 (2015).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Schlums, H. et al. Cytomegalovirus infection drives adaptive epigenetic diversification of NK cells with altered signaling and effector function. Immunity 42, 443–456 (2015).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Gao, F. et al. Biology and clinical relevance of HCMV-associated adaptive NK cells. Front. Immunol. 13, 830396 (2022).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Costa-Garcia, M. et al. Antibody-mediated response of NKG2Cbright NK cells against human cytomegalovirus. J. Immunol. 194, 2715–2724 (2015).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Ulbrecht, M. et al. Cutting edge: the human cytomegalovirus UL40 gene product contains a ligand for HLA-E and prevents NK cell-mediated lysis. J. Immunol. 164, 5019–5022 (2000).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Tomasec, P. et al. Surface expression of HLA-E, an inhibitor of natural killer cells, enhanced by human cytomegalovirus gpUL40. Science 287, 1031 (2000).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Powers, C. J. & Früh, K. Signal peptide-dependent inhibition of MHC class I heavy chain translation by rhesus cytomegalovirus. PLoS Pathog. 4, e1000150 (2008).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Brackenridge, S. et al. Regulation of the cell surface expression of classical and non-classical MHC proteins by the human cytomegalovirus UL40 and rhesus cytomegalovirus Rh67 proteins. J. Virol. 98, e0120624 (2024). This study shows that UL40 and Rh67 of HCMV and RhCMV, respectively, not only promote MHC-E egress to the cell surface via their VL9 sequences but also retain classical MHC-I proteins in the ER.

    Article 
    PubMed 

    Google Scholar 

  • Hammer, Q. et al. Peptide-specific recognition of human cytomegalovirus strains controls adaptive natural killer cells. Nat. Immunol. 19, 453–463 (2018). This paper shows that VL9 sequences determine NKG2C-dependent NK cell activation.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Koldehoff, M., Ross, S. R., Dührsen, U., Beelen, D. W. & Elmaagacli, A. H. Early CMV-replication after allogeneic stem cell transplantation is associated with a reduced relapse risk in lymphoma. Leuk. Lymphoma 58, 822–833 (2017).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Ram, D. R. et al. Tracking KLRC2 (NKG2C)+ memory-like NK cells in SIV+ and rhCMV+ rhesus macaques. PLoS Pathog. 14, e1007104 (2018).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Truitt, L. L. et al. Impact of CMV infection on natural killer cell clonal repertoire in CMV-naive rhesus macaques. Front. Immunol. 10, 2381 (2019).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Martin Almazan, N. et al. Non-classical HLA-E restricted CMV 15-mer peptides are recognized by adaptive NK cells and induce memory responses. Front. Immunol. 14, 1230718 (2023).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Wilkinson, G. W. et al. Modulation of natural killer cells by human cytomegalovirus. J. Clin. Virol. 41, 206–212 (2008).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Redondo-Pachon, D. et al. Adaptive NKG2C+ NK cell response and the risk of cytomegalovirus infection in kidney transplant recipients. J. Immunol. 198, 94–101 (2017).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Ataya, M. et al. Long-term evolution of the adaptive NKG2C+ NK cell response to cytomegalovirus infection in kidney transplantation: an insight on the diversity of host-pathogen interaction. J. Immunol. 207, 1882–1890 (2021).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Vietzen, H. et al. Extent of cytomegalovirus replication in the human host depends on variations of the HLA-E/UL40 axis. mBio 12, e02996–02920 (2021).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Vietzen, H., Pollak, K., Honsig, C., Jaksch, P. & Puchhammer-Stockl, E. NKG2C deletion is a risk factor for human cytomegalovirus viremia and disease after lung transplantation. J. Infect. Dis. 217, 802–806 (2018).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Mittelbronn, M. et al. Elevated HLA-E levels in human glioblastomas but not in grade I to III astrocytomas correlate with infiltrating CD8+ cells. J. Neuroimmunol. 189, 50–58 (2007).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Gooden, M. et al. HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8+ T lymphocytes. Proc. Natl Acad. Sci. USA 108, 10656–10661 (2011).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Benevolo, M. et al. High expression of HLA-E in colorectal carcinoma is associated with a favorable prognosis. J. Transl. Med. 9, 184 (2011).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Seliger, B. et al. HLA-E expression and its clinical relevance in human renal cell carcinoma. Oncotarget 7, 67360–67372 (2016).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Kamiya, T., Seow, S. V., Wong, D., Robinson, M. & Campana, D. Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells. J. Clin. Invest. 129, 2094–2106 (2019). This paper implicates NKG2A as a checkpoint for NK cell-mediated killing of tumour cells; see also Andre et al. (2018) and van Montfoort et al. (2018).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Iyer, R. F. et al. CD8+ T cell targeting of tumor antigens presented by HLA-E. Sci. Adv. 10, eadm7515 (2024). This work shows that RhCMV vectors expressing tumour-associated antigens elicit strong MHC-E-restricted T cell responses in non-human primates that cross-react with HLA-E-expressing human cancer cells.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Wen, M. et al. Expression and clinical significance of NKG2A and HLA-E in advanced laryngeal carcinoma. Pathol. Res. Pract. 260, 155383 (2024).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Liu, X. et al. Immune checkpoints HLA-E:CD94-NKG2A and HLA-C:KIR2DL1 complementarily shield circulating tumor cells from NK-mediated immune surveillance. Cell Discov. 10, 16 (2024).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Liu, X. et al. Immune checkpoint HLA-E:CD94-NKG2A mediates evasion of circulating tumor cells from NK cell surveillance. Cancer Cell 41, 272–287.e9 (2023).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • van Hall, T. et al. Monalizumab: inhibiting the novel immune checkpoint NKG2A. J. Immunother. Cancer 7, 263 (2019).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Lin, A. & Yan, W. H. Heterogeneity of HLA-G expression in cancers: facing the challenges. Front. Immunol. 9, 2164 (2018).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Liu, W. et al. FcRγ gene editing reprograms conventional NK cells to display key features of adaptive human NK cells. iScience 23, 101709 (2020).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Lo Monaco, E. et al. Human leukocyte antigen E contributes to protect tumor cells from lysis by natural killer cells. Neoplasia 13, 822–830 (2011).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Green, M. L. et al. CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia. Blood 122, 1316–1324 (2013).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Elmaagacli, A. H. et al. Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients. Blood 118, 1402–1412 (2011).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Cichocki, F. et al. Adaptive NK cell reconstitution is associated with better clinical outcomes. JCI Insight 4, e125553 (2019).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Litjens, N. H. R., van der Wagen, L., Kuball, J. & Kwekkeboom, J. Potential beneficial effects of cytomegalovirus infection after transplantation. Front. Immunol. 9, 389 (2018).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Chiu, E. et al. Anti-NKG2C/IL-15/anti-CD33 killer engager directs primary and iPSC-derived NKG2C+ NK cells to target myeloid leukemia. Mol. Ther. 29, 3410–3421 (2021).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Cho, H. et al. Adaptive natural killer cells facilitate effector functions of daratumumab in multiple myeloma. Clin. Cancer Res. 27, 2947–2958 (2021).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Bigley, A. B. et al. Latent cytomegalovirus infection enhances anti-tumour cytotoxicity through accumulation of NKG2C+ NK cells in healthy humans. Clin. Exp. Immunol. 185, 239–251 (2016).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Murad, S. et al. NKG2C+ NK cells for immunotherapy of glioblastoma multiforme. Int. J. Mol. Sci. 23, 5857 (2022).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Haroun-Izquierdo, A. et al. Adaptive single-KIR+NKG2C+ NK cells expanded from select superdonors show potent missing-self reactivity and efficiently control HLA-mismatched acute myeloid leukemia. J. Immunother. Cancer 10, e005577 (2022).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • van Montfoort, N. et al. NKG2A blockade potentiates CD8 T cell immunity induced by cancer vaccines. Cell 175, 1744–1755.e15 (2018). Using mouse models of cancer, this study shows that cancer vaccines elicit NKG2A-expressing T cells that are less effective at controlling cancers unless NKG2A is blocked.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Sheffer, M. et al. Genome-scale screens identify factors regulating tumor cell responses to natural killer cells. Nat. Genet. 53, 1196–1206 (2021).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Li, Y. et al. Unlocking the therapeutic potential of the NKG2A-HLA-E immune checkpoint pathway in T cells and NK cells for cancer immunotherapy. J. Immunother. Cancer 12, e009934 (2024). This work is a recent review of ongoing clinical studies of NKG2A-targeting and HLA-E-targeting immune checkpoint inhibitors.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Fisher, J. G., Graham, L. V. & Blunt, M. D. Strategies to disrupt NKG2A:HLA-E interactions for improved anti-cancer immunity. Oncotarget 15, 501–503 (2024).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Borst, L. et al. NKG2A is a late immune checkpoint on CD8 T cells and marks repeated stimulation and cell division. Int. J. Cancer 150, 688–704 (2022).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Abd Hamid, M. et al. Enriched HLA-E and CD94/NKG2A interaction limits antitumor CD8+ tumor-infiltrating T lymphocyte responses. Cancer Immunol. Res. 7, 1293–1306 (2019).

    Article 
    PubMed 

    Google Scholar 

  • Chen, Y. et al. CD8+ T cells form the predominant subset of NKG2A+ cells in human lung cancer. Front. Immunol. 10, 3002 (2019).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Fesneau, O. et al. IL-12 drives the expression of the inhibitory receptor NKG2A on human tumor-reactive CD8 T cells. Nat. Commun. 15, 9988 (2024).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Speiser, D. E. et al. In vivo expression of natural killer cell inhibitory receptors by human melanoma-specific cytolytic T lymphocytes. J. Exp. Med. 190, 775–782 (1999).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Ducoin, K. et al. Targeting NKG2A to boost anti-tumor CD8 T-cell responses in human colorectal cancer. Oncoimmunology 11, 2046931 (2022).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Salomé, B. et al. NKG2A and HLA-E define an alternative immune checkpoint axis in bladder cancer. Cancer Cell 40, 1027–1043.e9 (2022).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Battin, C. et al. NKG2A-checkpoint inhibition and its blockade critically depends on peptides presented by its ligand HLA-E. Immunology 166, 507–521 (2022).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Eugene, J. et al. The inhibitory receptor CD94/NKG2A on CD8+ tumor-infiltrating lymphocytes in colorectal cancer: a promising new druggable immune checkpoint in the context of HLAE/β2m overexpression. Mod. Pathol. 33, 468–482 (2020).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Haanen, J. B. & Cerundolo, V. NKG2A, a new kid on the immune checkpoint block. Cell 175, 1720–1722 (2018).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Aggarwal, C. et al. Updated results from COAST, a phase 2 study of durvalumab (D) ± oleclumab (O) or monalizumab (M) in patients (pts) with stage III unresectable non-small cell lung cancer (uNSCLC). J. Clin. Oncol. 42, 8046 (2024).

    Article 

    Google Scholar 

  • Barlesi, F. et al. PACIFIC-9: phase III trial of durvalumab + oleclumab or monalizumab in unresectable stage III non-small-cell lung cancer. Future Oncol. 20, 2137–2147 (2024).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Spinosa, P. et al. Quantitative modeling predicts competitive advantages of a next generation anti-NKG2A monoclonal antibody over monalizumab for the treatment of cancer. CPT Pharmacomet. Syst. Pharmacol. 10, 220–229 (2021).

    Article 
    CAS 

    Google Scholar 

  • Zhou, Y. et al. Generation, characterization, and preclinical studies of a novel NKG2A-targeted antibody BRY805 for cancer immunotherapy. Antibodies 13, 93 (2024).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Ravindranath, M. H., Filippone, E. J., Devarajan, A. & Asgharzadeh, S. Enhancing natural killer and CD8+ T cell-mediated anticancer cytotoxicity and proliferation of CD8+ T cells with HLA-E monospecific monoclonal antibodies. Monoclon. Antib. Immunodiagn. Immunother. 38, 38–59 (2019).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Hwang, J. K. et al. HLA-E-VL9 antibodies enhance NK cell and CD8+ T cell cytotoxicity against HIV-infected CD4+ T cells. Preprint at bioRxiv https://doi.org/10.1101/2024.07.08.602401 (2024).

  • Carlsten, M. et al. Bortezomib sensitizes multiple myeloma to NK cells via ER-stress-induced suppression of HLA-E and upregulation of DR5. Oncoimmunology 8, e1534664 (2019).

    Article 
    PubMed 

    Google Scholar 

  • Tsao, H.-W. et al. Targeting the aminopeptidase ERAP enhances antitumor immunity by disrupting the NKG2A-HLA-E inhibitory checkpoint. Immunity 57, 2863–2878 (2024). This study shows the utility of targeting ERAP (which is known to be required for VL9 processing for presentation by HLA-E) as a strategy for inhibiting HLA-E–NKG2A-mediated checkpoint control of NK cell and CD8+ T cell activity.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Fisher, J. G. et al. XPO1 inhibition sensitises CLL cells to NK cell mediated cytotoxicity and overcomes HLA-E expression. Leukemia 37, 2036–2049 (2023).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Westin, J. R. et al. Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: observations from the JULIET, ZUMA-1, and TRANSCEND trials. Am. J. Hematol. 96, 1295–1312 (2021).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Hong, M. & Chen, Y. Y. Killer fatigue: transition to NK-cell-like phenotype is a signature of CAR-T cell exhaustion. Cell 184, 6017–6019 (2021).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Good, C. R. et al. An NK-like CAR T cell transition in CAR T cell dysfunction. Cell 184, 6081–6100.e26 (2021).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Myers, J. A. & Miller, J. S. Exploring the NK cell platform for cancer immunotherapy. Nat. Rev. Clin. Oncol. 18, 85–100 (2021).

    Article 
    PubMed 

    Google Scholar 

  • Bexte, T. et al. CRISPR/Cas9 editing of NKG2A improves the efficacy of primary CD33-directed chimeric antigen receptor natural killer cells. Nat. Commun. 15, 8439 (2024). This paper shows that CAR NK cell activity against CD33-expressing target cells can be improved by gene editing to remove NKG2A expression.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Saetersmoen, M. et al. Targeting HLA-E-overexpressing cancers with a NKG2A/C switch receptor. Med 6, 100521 (2024). This paper shows that a fusion protein design of the NKG2A ligand-binding domain with the NKG2C signalling domain combines the increased affinity of NKG2A for VL9–HLA-E with the activating signalling provided by NKG2C.

    Article 
    PubMed 

    Google Scholar 

  • Voogd, L. et al. Mtb-specific HLA-E-restricted T cells are induced during Mtb infection but not after BCG administration in non-human primates and humans. Vaccines 12, 1129 (2024).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Mazzarino, P. et al. Identification of effector-memory CMV-specific T lymphocytes that kill CMV-infected target cells in an HLA-E-restricted fashion. Eur. J. Immunol. 35, 3240–3247 (2005).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Garcia, P. et al. Human T cell receptor-mediated recognition of HLA-E. Eur. J. Immunol. 32, 936–944 (2002).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Pietra, G. et al. HLA-E-restricted recognition of cytomegalovirus-derived peptides by human CD8+ cytolytic T lymphocytes. Proc. Natl Acad. Sci. USA 100, 10896–10901 (2003).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Romagnani, C. et al. HLA-E-restricted recognition of human cytomegalovirus by a subset of cytolytic T lymphocytes. Hum. Immunol. 65, 437–445 (2004).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Jouand, N. et al. HCMV triggers frequent and persistent UL40-specific unconventional HLA-E-restricted CD8 T-cell responses with potential autologous and allogeneic peptide recognition. PLoS Pathog. 14, e1007041 (2018). This study shows that UL40-encoded VL9 sequences can be targeted by HLA-E-restricted T cells in HCMV-infected humans.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Rousseliere, A., Delbos, L., Bressollette, C., Berthaume, M. & Charreau, B. Mapping and characterization of HCMV-specific unconventional HLA-E-restricted CD8 T cell populations and associated NK and T cell responses using HLA/peptide tetramers and spectral flow cytometry. Int. J. Mol. Sci. 23, 263 (2021).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Allard, M. et al. HLA-E-restricted cross-recognition of allogeneic endothelial cells by CMV-associated CD8 T cells: a potential risk factor following transplantation. PLoS ONE 7, e50951 (2012).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Sullivan, L. C. et al. The presence of HLA-E-restricted, CMV-specific CD8+ T cells in the blood of lung transplant recipients correlates with chronic allograft rejection. PLoS ONE 10, e0135972 (2015).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Waters, S. et al. Do variations in the HLA-E ligand encoded by UL40 distinguish individuals susceptible to HCMV disease? Hum. Immunol. 84, 75–79 (2022).

    Article 
    PubMed 

    Google Scholar 

  • Tarrago, D., Gonzalez, I. & Gonzalez-Escribano, M. F. HLA-E restricted cytomegalovirus UL40 peptide polymorphism may represent a risk factor following congenital infection. BMC Genom. 23, 455 (2022).

    Article 
    CAS 

    Google Scholar 

  • Sullivan, L. C. et al. Natural killer cell receptors regulate responses of HLA-E-restricted T cells. Sci. Immunol. 6, eabe9057 (2021).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Sullivan, L. C. et al. A conserved energetic footprint underpins recognition of human leukocyte antigen-E by two distinct αβ T cell receptors. J. Biol. Chem. 292, 21149–21158 (2017).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Hoare, H. L. et al. Structural basis for a major histocompatibility complex class Ib-restricted T cell response. Nat. Immunol. 7, 256–264 (2006).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Lo Monaco, E. et al. HLA-E: strong association with β2-microglobulin and surface expression in the absence of HLA class I signal sequence-derived peptides. J. Immunol. 181, 5442–5450 (2008).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Brackenridge, S., John, N., Früh, K., Borrow, P. & McMichael, A. J. The antibodies 3D12 and 4D12 recognise distinct epitopes and conformations of HLA-E. Front. Immunol. 15, 1329032 (2024).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Walters, L. C. et al. Pathogen-derived HLA-E bound epitopes reveal broad primary anchor pocket tolerability and conformationally malleable peptide binding. Nat. Commun. 9, 3137 (2018). This paper shows that HLA-E can bind a wide variety of peptides, and it suggests that some of the peptides targeted by CD8+ T cells bind very poorly to HLA-E.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Grant, E. J. et al. The unconventional role of HLA-E: the road less traveled. Mol. Immunol. 120, 101–112 (2020).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Pietra, G., Romagnani, C., Manzini, C., Moretta, L. & Mingari, M. C. The emerging role of HLA-E-restricted CD8+ T lymphocytes in the adaptive immune response to pathogens and tumors. J. Biomed. Biotechnol. 2010, 907092 (2010).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Lampen, M. H. et al. Alternative peptide repertoire of HLA-E reveals a binding motif that is strikingly similar to HLA-A2. Mol. Immunol. 53, 126–131 (2013).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • McMurtrey, C. et al. T cell recognition of Mycobacterium tuberculosis peptides presented by HLA-E derived from infected human cells. PLoS ONE 12, e0188288 (2017).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Ruibal, P. et al. Peptide binding to HLA-E molecules in humans, nonhuman primates, and mice reveals unique binding peptides but remarkably conserved anchor residues. J. Immunol. 205, 2861–2872 (2020).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Celik, A. A., Kraemer, T., Huyton, T., Blasczyk, R. & Bade-Doding, C. The diversity of the HLA-E-restricted peptide repertoire explains the immunological impact of the Arg107Gly mismatch. Immunogenetics 68, 29–41 (2016).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Kraemer, T. et al. HLA-E: presentation of a broader peptide repertoire impacts the cellular immune response-implications on HSCT outcome. Stem Cell Int. 2015, 346714 (2015).

    Google Scholar 

  • Weitzen, M., Shahbazy, M., Kapoor, S. & Caron, E. Deciphering the HLA-E immunopeptidome with mass spectrometry: an opportunity for universal mRNA vaccines and T-cell-directed immunotherapies. Front. Immunol. 15, 1442783 (2024).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • van Hall, T. et al. The varicellovirus-encoded TAP inhibitor UL49.5 regulates the presentation of CTL epitopes by Qa-1b1. J. Immunol. 178, 657–662 (2007).

    Article 
    PubMed 

    Google Scholar 

  • Guan, J., Peske, J. D., Taylor, J. A. & Shastri, N. The nonclassical immune surveillance for ERAAP function. Curr. Opin. Immunol. 70, 105–111 (2021).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Nagarajan, N. A., Gonzalez, F. & Shastri, N. Nonclassical MHC class Ib-restricted cytotoxic T cells monitor antigen processing in the endoplasmic reticulum. Nat. Immunol. 13, 579–586 (2012).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Doorduijn, E. M. et al. T cells engaging the conserved MHC class Ib molecule Qa-1b with TAP-independent peptides are semi-invariant lymphocytes. Front. Immunol. 9, 60 (2018).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Manoharan Valerio, M. et al. The promiscuous development of an unconventional Qa1b-restricted T cell population. Front. Immunol. 14, 1250316 (2023).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Geiger, K. M. et al. Murine cytomegalovirus downregulates ERAAP and induces an unconventional T cell response to self. Cell Rep. 42, 112317 (2023). This paper shows that downregulation of ERAAP by murine CMV results in the induction of T cells specific for Qa-1b presenting a similar self-peptide. The same Qa-1b-specific T cell population was observed in ERAAP-knockout mice by Nagarajan et al. (2012).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Picker, L. J., Lifson, J. D., Gale, M. Jr., Hansen, S. G. & Früh, K. Programming cytomegalovirus as an HIV vaccine. Trends Immunol. 44, 287–304 (2023). This work provides a comprehensive review on the ability of CMV vectors to elicit MHC-E-restricted T cells.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Walker, B. D. CMV, MHC-E, and the quest for an unconventional AIDS vaccine. Sci. Immunol. 6, eabi5830 (2021).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Barry, P. A. et al. Cytomegalovirus-vectored vaccines for HIV and other pathogens. AIDS 34, 335–349 (2020).

    Article 
    PubMed 

    Google Scholar 

  • Früh, K. & Picker, L. CD8+ T cell programming by cytomegalovirus vectors: applications in prophylactic and therapeutic vaccination. Curr. Opin. Immunol. 47, 52–56 (2017).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Sylwester, A. W. et al. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J. Exp. Med. 202, 673–685 (2005).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Kern, F. et al. Distribution of human CMV-specific memory T cells among the CD8pos. subsets defined by CD57, CD27, and CD45 isoforms. Eur. J. Immunol. 29, 2908–2915 (1999).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Masopust, D. & Picker, L. J. Hidden memories: frontline memory T cells and early pathogen interception. J. Immunol. 188, 5811–5817 (2012).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Hansen, S. G. et al. Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat. Med. 15, 293–299 (2009).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Hansen, S. G. et al. Addendum: Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat. Med. 17, 1692 (2011).

    Article 
    CAS 

    Google Scholar 

  • Hansen, S. G. et al. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 473, 523–527 (2011).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Hansen, S. G. et al. Immune clearance of highly pathogenic SIV infection. Nature 502, 100–104 (2013).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Hansen, S. G. et al. A live-attenuated RhCMV/SIV vaccine shows long-term efficacy against heterologous SIV challenge. Sci. Transl. Med. 11, eaaw2607 (2019).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Hansen, S. G. et al. Broadly targeted CD8+ T cell responses restricted by major histocompatibility complex E. Science 351, 714–720 (2016).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Hansen, S. G. et al. Cytomegalovirus vectors violate CD8+ T cell epitope recognition paradigms. Science 340, 1237874 (2013).

    Article 
    PubMed 

    Google Scholar 

  • Malouli, D. et al. Reevaluation of the coding potential and proteomic analysis of the BAC-derived rhesus cytomegalovirus strain 68-1. J. Virol. 86, 8959–8973 (2012).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Malouli, D. et al. Cytomegaloviral determinants of CD8+ T cell programming and RhCMV/SIV vaccine efficacy. Sci. Immunol. 6, eabg5413 (2021). This paper shows that multiple chemokine-like viral gene products independently prevent the induction of MHC-E-restricted T cells by CMV.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Malouli, D. et al. Cytomegalovirus-vaccine-induced unconventional T cell priming and control of SIV replication is conserved between primate species. Cell Host Microbe 30, 1207–1218.e7 (2022).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Malouli, D. et al. Human cytomegalovirus UL18 prevents priming of MHC-E- and MHC-II-restricted CD8+ T cells. Sci. Immunol. 9, eadp5216 (2024). This paper shows that HCMV UL18, a MHC-I-like LIR1 ligand, prevents the induction of MHC-E-restricted T cells when inserted into RhCMV.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Verweij, M. C. et al. Modulation of MHC-E transport by viral decoy ligands is required for RhCMV/SIV vaccine efficacy. Science 372, eabe9233 (2021). This study shows that viral VL9 peptides encoded in viral proteins are required for the induction of MHC-E-restricted T cells and that these T cells are required for protection against SIV.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Hansen, S. G. et al. Evasion of CD8+ T cells is critical for superinfection by cytomegalovirus. Science 328, 102–106 (2010).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Powers, C., DeFilippis, V., Malouli, D. & Früh, K. Cytomegalovirus immune evasion. Curr. Top. Microbiol. Immunol. 325, 333–359 (2008).

    CAS 
    PubMed 

    Google Scholar 

  • Hansen, S. G. et al. Myeloid cell tropism enables MHC-E-restricted CD8+ T cell priming and vaccine efficacy by the RhCMV/SIV vaccine. Sci. Immunol. 7, eabn9301 (2022).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Hansen, S. G. et al. Late gene expression-deficient cytomegalovirus vectors elicit conventional T cells that do not protect against SIV. JCI Insight 8, e164692 (2023).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Hansen, S. G. et al. Cytomegalovirus vectors expressing Plasmodium knowlesi antigens induce immune responses that delay parasitemia upon sporozoite challenge. PLoS ONE 14, e0210252 (2019).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Hansen, S. G. et al. Prevention of tuberculosis in rhesus macaques by a cytomegalovirus-based vaccine. Nat. Med. 24, 130–143 (2018).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Malouli, D. et al. Cytomegalovirus vaccine vector-induced effector memory CD4+ T cells protect cynomolgus macaques from lethal aerosolized heterologous avian influenza challenge. Nat. Commun. 15, 6007 (2024).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Burwitz, B. J. et al. MHC-E-restricted CD8+ T cells target hepatitis B virus-infected human hepatocytes. J. Immunol. 204, 2169–2176 (2020).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Wang, Y. et al. Ad5-nCoV vaccination could induce HLA-E restricted CD8+ T cell responses specific for epitopes on severe acute respiratory syndrome coronavirus 2 spike protein. Viruses 16, 5 (2023).

    Article 

    Google Scholar 

  • Hogan, M. J. et al. Cryptic MHC-E epitope from influenza elicits a potent cytolytic T cell response. Nat. Immunol. 24, 1933–1946 (2023).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Walters, L. C. et al. Primary and secondary functions of HLA-E are determined by stability and conformation of the peptide-bound complexes. Cell Rep. 39, 110959 (2022).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Walters, L. C., McMichael, A. J. & Gillespie, G. M. Detailed and atypical HLA-E peptide binding motifs revealed by a novel peptide exchange binding assay. Eur. J. Immunol. 50, 2075–2091 (2020).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Ruibal, P. et al. Discovery of HLA-E-presented epitopes: MHC-E/peptide binding and T-cell recognition. Methods Mol. Biol. 2574, 15–30 (2022).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Yang, H. et al. HLA-E-restricted SARS-CoV-2-specific T cells from convalescent COVID-19 patients suppress virus replication despite HLA class Ia down-regulation. Sci. Immunol. 8, eabl8881 (2023). This study shows that HLA-E-restricted, SARS-CoV-2-specific CD8+ T cells can be isolated and expanded from individuals with COVID-19.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Yang, H. et al. HLA-E-restricted, Gag-specific CD8+ T cells can suppress HIV-1 infection, offering vaccine opportunities. Sci. Immunol. 6, eabg1703 (2021). This paper shows that HLA-E-restricted HIV-specific T cells can be isolated and expanded from HIV-naive individuals.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Ruibal, P. et al. Identification of HLA-E binding Mycobacterium tuberculosis-derived epitopes through improved prediction models. J. Immunol. 209, 1555–1565 (2022).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Paterson, R. L. et al. An HLA-E-targeted TCR bispecific molecule redirects T cell immunity against Mycobacterium tuberculosis. Proc. Natl Acad. Sci. USA 121, e2318003121 (2024). This work determines that a bispecific antibody consisting of Mtb–HLA-E-specific TCR and anti-CD3 moieties can redirect T cells to M. tuberculosis-infected targeted cells.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Wallace, Z. et al. Instability of the HLA-E peptidome of HIV presents a major barrier to therapeutic targeting. Mol. Ther. 32, 678–688 (2024).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Lemberg, M. K., Bland, F. A., Weihofen, A., Braud, V. M. & Martoglio, B. Intramembrane proteolysis of signal peptides: an essential step in the generation of HLA-E epitopes. J. Immunol. 167, 6441–6446 (2001).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Weihofen, A., Lemberg, M. K., Ploegh, H. L., Bogyo, M. & Martoglio, B. Release of signal peptide fragments into the cytosol requires cleavage in the transmembrane region by a protease activity that is specifically blocked by a novel cysteine protease inhibitor. J. Biol. Chem. 275, 30951–30956 (2000).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Bland, F. A., Lemberg, M. K., McMichael, A. J., Martoglio, B. & Braud, V. M. Requirement of the proteasome for the trimming of signal peptide-derived epitopes presented by the nonclassical major histocompatibility complex class I molecule HLA-E. J. Biol. Chem. 278, 33747–33752 (2003).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Coupel, S. et al. Expression and release of soluble HLA-E is an immunoregulatory feature of endothelial cell activation. Blood 109, 2806–2814 (2007).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Hengel, H. et al. A viral ER-resident glycoprotein inactivates the MHC-encoded peptide transporter. Immunity 6, 623–632 (1997).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Ahn, K. et al. The ER-luminal domain of the HCMV glycoprotein US6 inhibits peptide translocation by TAP. Immunity 6, 613–621 (1997).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Park, B. et al. Human cytomegalovirus inhibits tapasin-dependent peptide loading and optimization of the MHC class I peptide cargo for immune evasion. Immunity 20, 71–85 (2004).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Prod’homme, V. et al. Human cytomegalovirus UL40 signal peptide regulates cell surface expression of the NK cell ligands HLA-E and gpUL18. J. Immunol. 188, 2794–2804 (2012).

    Article 
    PubMed 

    Google Scholar 

  • Davis, Z. B. et al. A conserved HIV-1-derived peptide presented by HLA-E renders infected T-cells highly susceptible to attack by NKG2A/CD94-bearing natural killer cells. PLoS Pathog. 12, e1005421 (2016).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Hannoun, Z. et al. Identification of novel HIV-1-derived HLA-E-binding peptides. Immunol. Lett. 202, 65–72 (2018).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Romero-Martin, L. et al. Disruption of the HLA-E/NKG2X axis is associated with uncontrolled HIV infections. Front. Immunol. 13, 1027855 (2022).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Peppa, D. et al. Adaptive reconfiguration of natural killer cells in HIV-1 infection. Front. Immunol. 9, 474 (2018).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Guma, M. et al. Human cytomegalovirus infection is associated with increased proportions of NK cells that express the CD94/NKG2C receptor in aviremic HIV-1-positive patients. J. Infect. Dis. 194, 38–41 (2006).

    Article 
    PubMed 

    Google Scholar 

  • Mela, C. M. et al. Switch from inhibitory to activating NKG2 receptor expression in HIV-1 infection: lack of reversion with highly active antiretroviral therapy. AIDS 19, 1761–1769 (2005).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Mela, C. M. & Goodier, M. R. The contribution of cytomegalovirus to changes in NK cell receptor expression in HIV-1-infected individuals. J. Infect. Dis. 195, 158–159 (2007).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Maidji, E., Somsouk, M., Rivera, J. M., Hunt, P. W. & Stoddart, C. A. Replication of CMV in the gut of HIV-infected individuals and epithelial barrier dysfunction. PLoS Pathog. 13, e1006202 (2017).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Jost, S. et al. Antigen-specific memory NK cell responses against HIV and influenza use the NKG2/HLA-E axis. Sci. Immunol. 8, eadi3974 (2023).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Hasan, M. Z. et al. SARS-CoV-2 infection induces adaptive NK cell responses by spike protein-mediated induction of HLA-E expression. Emerg. Microbes Infect. 13, 2361019 (2024).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Hammer, Q. et al. SARS-CoV-2 Nsp13 encodes for an HLA-E-stabilizing peptide that abrogates inhibition of NKG2A-expressing NK cells. Cell Rep. 38, 110503 (2022).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Alrubayyi, A. et al. Natural killer cell responses during SARS-CoV-2 infection and vaccination in people living with HIV-1. Sci. Rep. 13, 18994 (2023).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Huot, N. et al. SARS-CoV-2 viral persistence in lung alveolar macrophages is controlled by IFN-γ and NK cells. Nat. Immunol. 24, 2068–2079 (2023).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Vietzen, H. et al. Torque teno viruses exhaust and imprint the human immune system via the HLA-E/NKG2A axis. Front. Immunol. 15, 1447980 (2024).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Vietzen, H. et al. HLA-E-restricted immune responses are crucial for the control of EBV infections and the prevention of PTLD. Blood 141, 1560–1573 (2022).

    Article 
    PubMed Central 

    Google Scholar 

  • Vietzen, H., Hartenberger, S., Aberle, S. W. & Puchhammer-Stöckl, E. Dissection of the NKG2C NK cell response against Puumala orthohantavirus. PLoS Negl. Trop. Dis. 15, e0010006 (2021).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Antrobus, R. D. et al. Virus-specific cytotoxic T lymphocytes differentially express cell-surface leukocyte immunoglobulin-like receptor-1, an inhibitory receptor for class I major histocompatibility complex molecules. J. Infect. Dis. 191, 1842–1853 (2005).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Wu, H. L. et al. The role of MHC-E in T cell immunity is conserved among humans, rhesus macaques, and cynomolgus macaques. J. Immunol. 200, 49–60 (2018).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Picker, L. J., Hansen, S. G. & Lifson, J. D. New paradigms for HIV/AIDS vaccine development. Annu. Rev. Med. 63, 95–111 (2012).

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Pfeiffer, T. et al. Posoleucel, an allogeneic, off-the-shelf multivirus-specific T-cell therapy, for the treatment of refractory viral infections in the post-HCT setting. Clin. Cancer Res. 29, 324–330 (2023).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

Continue Reading

  • Scrolling on the toilet increases your risk of haemorrhoids, new study shows

    Scrolling on the toilet increases your risk of haemorrhoids, new study shows

    Many of us are guilty of scrolling our smartphones on the toilet. But a new study from the United States, published today, has found this habit may increase your risk of developing haemorrhoids by up to 46%.

    So, what’s the link? How can time on your phone lead to these painful lumps in and around your anus? Here’s what we know.

    What are haemorrhoids?

    Every healthy person has haemorrhoids, sometimes called piles. They are columns of cushioned tissue and blood vessels found close to the opening of the anus.

    We don’t notice haemorrhoids until they’re symptomatic.
    Aleksandr Kharitonov/Getty

    Haemorrhoids have a really important role in maintaining bowel continence or, to put it simply, keeping your poo in.

    When all is well, we don’t notice them. But haemorrhoids can get swollen and this can lead to symptoms such as pain, bleeding or feeling a lump just inside your anus (internal haemorrhoids) or protruding outside (external haemorrhoids).

    So when someone “has haemorrhoids”, it means they have become inflamed or symptomatic.

    This is extremely common: more than one in two of us will experience symptomatic haemorrhoids at some point in our lives.

    You are more likely to get haemorrhoids if you:

    • are older (over 45)
    • are pregnant
    • are overweight
    • have persistent constipation or diarrhoea
    • regularly lift heavy objects
    • spend a lot of time on the toilet.

    The link between toilet time and haemorrhoids

    Prolonged sitting in general has not been linked to developing haemorrhoids.

    However, a standard toilet seat – unlike a chair or couch – has a large internal opening that provides no support for the pelvic floor (the group of muscles and ligaments that support the bladder, bowel and uterus).

    Prolonged sitting on a toilet seat is believed to increase pressure inside the pelvic floor and lead to blood pooling in the vascular cushions of the anus. This makes haemorrhoids more likely to develop.

    What the new study looked at

    The new US study recruited 125 adults, aged 45 and older, who were undergoing a colonoscopy at Beth Israel Deaconess Medical centre.

    Researchers surveyed them about their smartphone habits while using the toilet, including how often they checked their phone and for how long. Participants also reported on other behaviours such as straining, their fibre intake, and how much physical activity they did.

    The researchers recorded whether they had haemorrhoids. Since the participants were all having a colonoscopy, the presence of internal haemorrhoids could be directly confirmed visually.

    What did the study show?

    Two-thirds (66%) of all participants used smartphones while on the toilet. The most common activity was reading news (54.3%), followed by social media (44.4%).

    Those who used their smartphones spent longer on the toilet than those who didn’t. More than one in three (37.3%) toilet smartphone users spent over five minutes on the toilet, compared to just over one in 20 (7%) of those who didn’t use their smartphones.

    The smartphone users had a 46% higher risk of haemorrhoids, compared to those who didn’t use their smartphone. To calculate this, researchers took into account other known risk factors for haemorrhoids such as gender, age, body mass index, exercise activity, straining and fibre intake.

    However, unlike some other research, this study did not find a link between straining and haemorrhoids.

    As a result, the researchers concluded that time spent on the toilet poses a more significant risk for haemorrhoids than straining. However, we can’t rule out straining as a risk factor, based on one study.

    Some other limitations to consider

    The study relied on participants remembering whether or not they strained, and how long they spent on the toilet.

    This kind of recall is subjective, and may also be influenced by taking part in the study. For example, if the participants thought they had haemorrhoids, they may be more likely to report straining.

    The study’s small sample size and the participants’ age (all over 45) also mean it is unlikely to be representative of the broader population.

    Toilet sitting time

    The new study is not the first to study the link between time spent on the toilet and developing haemorrhoids. In 2020, a Turkish study found spending more than five minutes on the toilet was associated with haemorrhoids.

    Another 2020 study from Italy of 52 people with diagnosed internal or external haemorrhoids noted the longer they spent on the toilet, the more severe their haemorrhoids.



    Read more:
    Do men really take longer to poo?

    So, what are we doing on the toilet?

    Defaecation itself usually doesn’t take long. One study found it took healthy adults an average two minutes when sitting, but only 51 seconds when squatting.

    The majority of “toilet sitting time” usually means just that – sitting on the toilet, doing other activities aside from pooing (or weeing).

    One 2008 study from Israel surveyed 500 adults and found more than half (52.7%) read books or newspapers while on the toilet. It also found toilet readers spent significantly more time on the toilet.

    How to avoid haemorrhoids

    The usual advice is to increase the amount of fibre in your diet (eating more fruit, vegetables and wholegrains) and ensure you drink enough water. This makes it easier to pass a stool and reduces straining – which you should also try to avoid.

    However, the new research confirms previous evidence that cutting down toilet sitting time may also help. So, avoiding distractions by leaving your smartphone outside the bathroom is a good idea (and as a bonus, will expose your device to fewer germs).



    Read more:
    Your phone is covered in germs: a tech expert explains how to clean it without doing damage

    If you have any concerning symptoms, such as blood in your stool, a new lump in the anal region, or pain when passing a bowel motion then you should see your local doctor for further investigations and treatment.

    Continue Reading

  • Sweeteners can harm cognitive health equivalent to 1.6 years of ageing, study finds | Food

    Sweeteners can harm cognitive health equivalent to 1.6 years of ageing, study finds | Food

    Sweeteners found in yoghurts and fizzy drinks can damage people’s ability to think and remember, and appear to cause “long-term harm” to health, research has found.

    People who consumed the largest amount of sweeteners such as aspartame and saccharin saw a 62% faster decline in their cognitive powers – the equivalent to their having aged 1.6 years, researchers say.

    They concluded: “Our findings suggest the possibility of long-term harm from low- and no-calorie sweeteners (LNCs) consumption, particularly artificial LNCs and sugar alcohols, on cognitive function.”

    The findings are the latest to warn about the dangers posed by sweeteners. Previous studies have suggested they may increase the risk of a range of diseases including type 2 diabetes, cancer, heart problems, depression and dementia, and damage the gut wall.

    Sweeteners’ association with cognitive decline is of such concern that consumers should instead use either tagatose, a natural sweetener, or alternatives such as honey or maple syrup, the researchers said.

    They looked at the impact of seven sweeteners on the health of the study’s participants – 12,772 civil servants in Brazil, with an average age of 52 – who were followed up for on average eight years. Participants completed questionnaires detailing their food and drink intake over the previous year, and later underwent tests of their cognitive skills such as verbal fluency and word recall.

    People who consumed the most sweeteners experienced declines in their thinking and memory skills 62% faster than those with the lowest intake, the researchers found. This was “the equivalent of about 1.6 years of ageing”, the researchers said.

    Consumption of combined and individual LNCs, particularly aspartame, saccharin, acesulfame K, erythritol, sorbitol and xylitol, was associated with cognitive loss.

    “Daily consumption of LNCs was associated with accelerated decline in memory, verbal fluency and global cognition,” the authors say in their paper, published in the American medical journal Neurology.

    However, the trend was only observed in participants under the age of 60. That shows that middle-aged adults need to be encouraged to use fewer sweeteners, they added.

    The sweeteners studied are also found in flavoured water, low-calorie desserts and energy drinks.

    “Low and no-calorie sweeteners are often seen as a healthy alternative to sugar. However, our findings suggest certain sweeteners may have negative effects on brain health over time,” said Claudia Kimie Suemoto, of the University of São Paulo in Brazil, the study’s lead author.

    Food and drink industry bodies cast doubt on the findings. “By the authors’ own admission, this study cannot prove cause,” said Gavin Partington, the director general of the British Soft Drinks Association.

    “Non-sugar sweeteners are safe, according to all leading health authorities in the world, and that’s why they have been used in a vast array of food, medicine, dental and drinks products for many decades.

    “Their use in soft drinks has helped UK manufacturers to remove just under three-quarters of a billion kilograms of sugar from product since 2015.”

    The International Sweeteners Association (ISA) said there was an “established scientific consensus” that sweeteners are safe.

    “This research is an observational study, which can only show a statistical association, not a direct cause-and-effect relationship,” the ISA said in a statement. “The reported link between sweetener consumption and cognitive decline does not prove that one causes the other.”

    Continue Reading

  • Downton Abbey: The Grand Finale review – this silly, enjoyable nonsense should go on for ever | Film

    Downton Abbey: The Grand Finale review – this silly, enjoyable nonsense should go on for ever | Film

    Grand finale? Oh please. Let’s get real; there is no reason why this particular brand of gibbering, wittering, blithering and surreally enjoyable nonsense shouldn’t go on for ever, like Frank Sinatra’s farewell tour or shortbread manufacture in the Scottish Highlands. Both of the previous Downton films had a sentimental last-hurrah message that didn’t preclude another one dropping off the production line. We could make the next film Downton Abbey: The Royal Finale and the one after that Downton Abbey: The Imperial Finale.

    The last but one film finished on a funereal drone shot of Downton Abbey at sunset and the one after that was subtitled “A New Era” – but this one, it seems, has taken us back to the very end of the old era, inviting us to swoon loyally at the passing of something special and yet also at the same time doff our caps at the bluebloods’ insouciant gift for survival. There is something entertainingly outrageous in the pure tongue-in-cheek craziness of this new film’s opening sequence; it could almost count as a dadaist dream sequence. I don’t think anything in the TV show or the movies had anything as mickey-takingly bizarre.

    The scene is London in 1930 and Lady Mary (Michelle Dockery) is at a grand society occasion with her parents, the Earl of Grantham (Hugh Bonneville) and the Countess of Grantham (Elizabeth McGovern), when the rumour runs round the assembled company that – gasp! – Lady Mary is technically a divorced woman and so has to be expelled from the party before the royals turn up. The shock of Lady Mary being divorced is presented with impeccable seriousness, like news of a terrorist bomb. Julian Fellowes is, of course, sporting with us, and yet you can’t help smiling along. Fellowes also once again cheekily recycles an idea from his country-house screenplay Gosford Park from 2001, directed by Robert Altman; in that film he had Ivor Novello turning up as a guest, now it’s Noël Coward (Arty Froushan), whose celebrity presence at Downton convinces all the local nobility to accept Lady Mary’s status as a divorcee.

    Life at Downton is as eventful as ever, with Lord G brooding on whether to accept Lady Mary’s succession as the mistress of the house, and graciously retreat with his wife to the “Dower House” occupied by his late mother. A rather gruesome Hammer horror portrait of the late Maggie Smith now dominates the building. Lady Grantham’s sheepish American brother Harold (Paul Giamatti) comes to stay with his smoothie financial adviser Gus Sambrook (Alessandro Nivola); the latter gives Lady Mary the eye. And below stairs, housekeeper Elsie Hughes (Phyllis Logan) calms the premarital nerves of Mrs Patmore (Lesley Nicol), assuring her that conjugal responsibilities are in fact “terrific fun!” (The film should get an 18 certificate for this line alone.)

    The film is very silly and always watchable in its weird way, with those eccentrically emphasised shots of characters thanking each other for their thoughtfulness. The next Downton Abbey film will surely have to make these characters absorb the rise of fascism and the stormclouds of war. It promises to be a diverting spectacle.

    Downton Abbey: The Grand Finale is out on 11 September in Australia, and on 12 September in the UK and US.

    Continue Reading

  • Artificial sweeteners consumed in midlife linked to cognitive decline

    Artificial sweeteners consumed in midlife linked to cognitive decline

    Sept. 2 (UPI) — People who consume the highest levels of artificial sweeteners during middle age show the fastest declines in cognitive functions, such as memory, as they move into their senior years, according to a study released Wednesday.

    The study of nearly 13,000 middle-aged Brazilian adults who were followed for an average of eight years revealed that those who consumed the most aspartame, saccharin and five other kinds of sweeteners experienced cognitive declines at a 62% faster clip than those who consumed the lowest amounts, the researchers said.

    That difference equates to about 1.6 years of aging, according to the study published in the journal Neurology.

    The link between sweeteners and the rapidity of decline was even stronger in people with diabetes, particularly for memory loss.

    However, there appeared to be no effect in participants aged 60 and older. This suggests exposure to artificial sweeteners during midlife — when many people turn to them to lose weight — may carry lifelong consequences for brain health, according to the researchers from the University of Sao Paulo and elsewhere in Brazil.

    The seven artificial sweeteners studied were aspartame, saccharin, acesulfame k, erythritol, sorbitol, xylitol and tagatose. Daily consumption of any or all them in midlife was associated with accelerated decline in memory, verbal fluency and global cognition in later years, the researchers reported.

    The study, supported by the Brazilian Ministry of Health, had some limitations, including that the diet information used was reported by the participants themselves, and they may not have remembered accurately everything they ate.

    It builds on earlier work by the Brazilian researchers connecting ultra-processed foods with faster cognitive decline. Many such foods marketed as sugar-free contain artificial sweeteners, noted co-author Claudia Kimie Suemoto, an associate professor of geriatrics at the University of Sao Paulo.

    “By following more than 12,000 adults for eight years, our study adds robust evidence that these compounds may not be harmless, particularly when consumed frequently and starting in midlife,” she told UPI in emailed comments.

    “In the broader scientific context, our findings highlight the need to look more critically at what we are using to replace sugar in our diets, and they underscore that dietary choices in midlife can have consequences for brain health decades later.”

    Suemoto said her study is the largest and longest prospective study to date investigating the association between artificial sweetener consumption and cognitive decline, adding that the few studies published on the topic previously had smaller samples and followed participants for shorter periods of time.

    “Moreover, while previous research had linked sweeteners to conditions such as diabetes, cardiovascular disease and depression, their long-term impact on cognition had not been systematically explored,” she added.

    One of the most surprising findings, she said, was that the association between low- and no-calorie sweetener consumption and cognitive decline was only significant among participants younger than 60.

    “I had expected the association to be more evident in older adults, since they are at higher risk of dementia and cognitive impairment,” Suemoto said. “Instead, our results suggest that midlife exposure to sweeteners may be particularly harmful, which is important because midlife is a critical period for setting the trajectory of brain health.

    “Cognitive decline and dementia are thought to begin developing decades before symptoms become noticeable, so exposures during midlife may accelerate these processes and have long-term consequences.”

    The key takeaway is a new understanding of the importance of getting a handle on dietary habits earlier in adulthood, “when preventive strategies could have the greatest impact,” she said.

    The Brazilian findings intertwine with what already was suspected about the negative effects of low-calorie sweeteners on brain health, said Pradeep Bhide, the Jim and Betty Ann Rodgers Eminent Scholar Chair of Developmental Neuroscience at Florida State University and director of FSU’s Institute for Pediatric Rare Diseases.

    He told UPI the results “echo” his findings from a 2022 study on aspartame, in which he found that daily consumption in mice can lead to behavioral and cognitive impairments, such as anxiety-like behavior, learning deficits and memory impairment, likely due to the sweetener’s effects on the brain’s neurotransmitter systems.

    “Importantly, our own experimental studies also demonstrated that these effects were not limited to the exposed individuals, but were transmitted from aspartame-exposed fathers to their offspring across two generations,” he said.

    Despite the Brazilian study’s limitations, its combination of large-scale human data and controlled laboratory findings “strengthens the concern that chronic exposure to artificial sweeteners may have significant neurobehavioral consequences,” Bhide said.

    “These results underscore the need for caution in the widespread use of such sweeteners and highlight the importance of further mechanistic studies.”

    Theresa Gentile, a registered dietitian nutritionist and spokeswoman for the Academy of Nutrition and Dietetics, said the study highlights a possible “worsening” of risk for those with diabetes and cerebrovascular disease.

    “Many people choose sugar-free or ‘diet’ products thinking they’re the healthier option, but this research suggests that they might not be the best choice for brain health,” she told UPI. “Overall, the study highlights that being careful with sweetener choices could help protect both blood vessel health and memory.”

    The study reinforces earlier evidence linking sweeteners to health risks like and “adds weight by showing that many of the same sweeteners may also harm brain health over the long term,” she said.

    It also “supports the gut-brain connection, since changes in gut bacteria and inflammation are possible ways these sweeteners could affect memory and thinking.”

    Meanwhile, the study demonstrated that not every sweetener is the same regarding cognition. Tagatose, sold as a lower-calorie alternative to sucrose, “stood out as not being linked to cognitive decline, which suggests some natural sweeteners may be better options for cognition than others,” Gentile added.

    Continue Reading

  • Artificial sweeteners may speed up brain ageing, study claims

    Artificial sweeteners may speed up brain ageing, study claims

    Artificial sweeteners may carry unexpected risks for brain health, a new study claims.

    A study published in Neurology examined the diets of more than 12,700 adults in Brazil, and found that those who consumed the highest amounts of low- or no-calorie sweeteners experienced faster declines in memory and thinking skills over an eight-year period.

    The effect was particularly pronounced among people with diabetes and those under 60. 

    The researchers assessed seven sweeteners commonly found in diet sodas, flavoured waters, yoghurts and low-calorie desserts: aspartame, saccharin, acesulfame-K, erythritol, xylitol, sorbitol and tagatose.

    Of these, all except tagatose were linked to cognitive decline, especially in memory and verbal fluency.

    Participants were divided into three groups based on their intake. Those consuming the most – around 191 milligrams a day, the equivalent of a single can of diet soda for aspartame – showed cognitive decline 62 per cent faster than those consuming the least, roughly equal to an extra 1.6 years of ageing.

    “Low- and no-calorie sweeteners are often seen as a healthy alternative to sugar, however, our findings suggest certain sweeteners may have negative effects on brain health over time,” said study author Prof Claudia Kimie Suemoto of the University of São Paulo.

    “Previous research had linked artificial sweeteners to conditions like diabetes, cancer, cardiovascular disease and depression, but their potential impact on cognition had not been investigated.”

    Consuming artificial sweeteners in amounts similar to a daily can of diet soda was associated with faster cognitive decline, equivalent to 1.6 years of brain ageing – Credit: Getty

    One of the more surprising results was that the link appeared only in adults younger than 60. 

    “I had expected the association to be more evident in older adults, since they are at higher risk of dementia and cognitive impairment,” Suemoto said. “Instead, our results suggest that midlife exposure to sweeteners may be particularly harmful, which is important because midlife is a critical period for setting the trajectory of brain health.”

    The findings do not prove that sweeteners directly cause cognitive decline. Factors such as self-reported diet and the absence of all types of sweeteners in the study are limitations. 

    Still, Suemoto said the results warrant caution and further research, including brain imaging and mechanistic studies of gut health and inflammation.

    Her team is already working on neuroimaging studies to understand what could be causing the link, the results of which are not yet available. 

    “More research is needed to confirm our findings and to investigate if other refined sugar alternatives, such as applesauce, honey, maple syrup or coconut sugar, may be effective alternatives,” Suemoto said.

    About our expert

    Claudia Suemoto is an assistant professor at the University of São Paulo, Brazil. She’s also a trained physician whose research has been published in journals such as The Lancet, Nature Neuroscience and The Journal of Alzheimer’s Disease.

    Read more:

    Continue Reading

  • ‘Downton Abbey: The Grand Finale’ Review: Beloved Series Ends

    ‘Downton Abbey: The Grand Finale’ Review: Beloved Series Ends

    The title says it all.

    Downton Abbey: The Grand Finale is the end of the beloved tale of the Crawley family over several years, first as a limited and then regular TV drama series, and then as major motion pictures, with this the third and apparently last of them. Writer-producer Julian Fellowes has created such a memorable group of characters it is hard to finally say goodbye to them, but in this witty and wise finale it is nice to report it is a goodbye worth saying, with somehow each of the members of this massive ensemble cast getting their moment in the sunset. Even though the absence of the great late Maggie Smith as the inimitable Violet is felt, it really isn’t because she is often mentioned and there is a wonderful and touching dedication to her at the end. This is all about a changing of the guard at Downton Abbey, a new era beginning as they all celebrate summer of 1930 with the annual Peterfield’s Ball.

    Things open, however, with a scandal. Lady Mary’s (Michelle Dockery) divorce is almost final, and as she arrives back at Downton there is a feeling she is going to be shunned — divorce is something forbidden in this British class, and it could well derail plans for her future elevation. On another front it is the final summer for Mr. Carson (Jim Carter), who is retiring as head butler, to be replaced by the younger Andy (Michael Fox). Adding to the shakeup is the impending retirement as well of the lovable Mrs. Patmore (Lesley Nicol) in a few weeks. Times are bittersweet for Lord Grantham aka Robert (Hugh Bonneville) and Cora (Elizabeth McGovern) as he mulls, regrettably, turning over the leadership of Downton Abbey to Mary, even though this could not be a worse time in the scheme of things. He has been such a force, but times change.

    Financial woes are prevalent as well, emphasized with the arrival of American cousin Harold (Paul Giamatti), who has settled the estate with the help of Gus Sambrook (Alessandro Nivola), a newcomer to Downton who weaves his charm instantly with Mary resulting in a passionate one-night stand she may learn to regret. The finances also are wobbly here as all the money left behind by the Dowager Countess has been squandered. But how? The suggestion that maybe they need to sell off their London estate, Grantham House, is met with a rare explosion of temper by Robert who rules it out with fierce force.

    Of course this is just a huge cast but this edition is dominated by Dockery’s Mary, navigating being in the eye of a storm but also showing dignity and smarts in the process. Bonneville retains his dignity even as events change around him and the always welcome McGovern’s Cora. Fan favorites Carter and Nicol get proper farewells and treat them with grace. It is fun to see Giamatti, whose character Harold was last in the TV series more than a decade ago, and with him the slick and sexy newcomer Sambrook played with sly charm by Nivola, bringing forth a interloper who may not be who he says he is. That discovery is due to the return of Tom, again nicely played by Allen Leach, who is in cahoots with Laura Carmichael’s feisty Edith to get to the truth, if only for the sake of this entire family empire.

    Others include Lady Merton aka Isobel (the wonderful Penelope Wilton) getting new power running the annual county fair, much to the distaste of the man who thinks he is in charge, Sir Hector Moreland (Simon Russell Beale). A welcome newcomer to Downton is none other than Noel Coward (Arty Froushan), who comes to a dinner and performs on a night all troubles are forgotten. There is also news of a new generation emerging in this landscape with the pregnancy of Anna Bates, played again by Joanne Froggatt, the second child for her and Mr. Bates (Brendan Coyle). There is also a charming story thread for Footman Mr. Moseley (Kevin Doyle stealing scenes), who has written a movie and is working on a second as he forges a second career outside of the service job at Downton. “You know the real stars are the writers!” he says enthusiastically, and with a wink from Fellowes who is perhaps commenting on his own contribution to his irresistible franchise.

    There are so many characters, so many storylines weaved in and out, you have to properly also give credit to returning director Simon Curtis for keeping them all straight and so naturally intertwined in the fast-paced goodbye that comes in just over a tight two hours and never feels rushed, never feels like cramming in too much to please the fans. It is a tall order, and Curtis’ elegant and assured guidance, along with Fellowes’ customarily witty and engaging scenario, make this the best Downton movie of them all, one I have to admit shedding a tear or two by the time it ended.

    Producers are Fellowes and Liz Trubridge.

    Title: Downton Abbey: The Grand Finale
    Distributor: Focus Features
    Release date: September 12, 2025
    Director: Simon Curtis
    Screenwriter: Julian Fellowes
    Cast: Hugh Bonneville, Laura Carmichael, Jim Carter, Raquel Cassidy, Paul Copley, Brendan Coyle, Michelle Dockery, Kevin Doyle, Michael Fox, Paul Giamatti, Joanne Froggatt, Harry Hadden-Paton, Robert James-Collier, Allen Leach, Phyllis Logan, Elizabeth McGovern, Sophie McShera, Lesley Nicol, Penelope Wilton, Douglas Reith, Alessandro Nivola, Arty Froushan, Joely Richardson, Dominic West, Simon Russell Beale
    Rating: PG
    Running Time: 2 hr 3 mins

    Continue Reading

  • As Trump chills US-India ties, Modi warms to China and Russia – Reuters

    1. As Trump chills US-India ties, Modi warms to China and Russia  Reuters
    2. Xi Jinping’s anti-American party  The Economist
    3. Trump’s rebuke, Xi’s handshake, Putin’s oil: India’s foreign policy test  BBC
    4. Opinion | No, This Is Not About Ganging Up Against The US  NDTV
    5. Trump is the Elephant in the Room at the SCO Summit | Vantage with Palki Sharma | N18G  Firstpost

    Continue Reading

  • Groundbreaking study shows lifestyle changes significantly improve brain health – The Business Journals

    1. Groundbreaking study shows lifestyle changes significantly improve brain health  The Business Journals
    2. More people thinking about their mental acuity  Dayton Daily News
    3. Can diet alone slow brain aging? Scientists say evidence is still too weak  News-Medical
    4. Harvard experts recommend this exercise to keep seniors’ minds sharp in retirement – Metabolic  OkDiario
    5. Mind over age: How to keep your brain healthy  University of Alabama at Birmingham

    Continue Reading